Comprehensive Study of Human Glioblastoma Multiforme Including Normal, Tumor, and Metastasis Tissues

What this Trial Is About

Researchers are conducting an integrative analysis of human glioblastoma multiforme GBM by studying the proteomes, transcriptomes, and genomic profiles of paired normal brain tissues, primary GBM tumors, and their matched metastases. This involves combining various data types, including whole exome sequencing and SNP array profiling, as well as analyzing existing genomic data from The Cancer Genome Atlas TCGA. The study collects samples from GBM patients, including normal brain tissue, primary tumor tissue, and metastasis tissue. From these samples, investigators extract total protein, DNA, and RNA to perform detailed molecular analyses and conduct integrated proteogenomic evaluations. This is an observational study without intervention or treatment administration. Participants undergo tissue sampling and molecular data collection for research purposes. The main outcome measured is 5-year overall survival, with secondary outcomes including 5-year and 10-year disease-free survival and overall survival. The study spans multiple years to assess long-term outcomes. Participants will be monitored according to the study schedule, but no treatment is provided as part of this trial.

Integrative Analysis of Human Glioblastoma Multiforme